Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

PURPOSE: This phase I study of the mitogen-activated protein/extracellular signal-regulated kinase inhibitor RO4987655 (CH4987655) assessed its maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetic/pharmacodynamic profile, and antitumor activity in patients with advan...

Full description

Bibliographic Details
Main Authors:	Leijen, S, Middleton, MR, Tresca, P, Kraeber-Bodéré, F, Dieras, V, Scheulen, M, Gupta, A, Lopez-Valverde, V, Xu, Z, Rueger, R, Tessier, J, Shochat, E, Blotner, S, Naegelen, V, Schellens, J, Eberhardt, W
Format:	Journal article
Language:	English
Published:	2012

Similar Items

Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.
by: Kraeber-Bodéré, F, et al.
Published: (2012)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
by: Leijen, S, et al.
Published: (2011)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
by: Leijen, S, et al.
Published: (2011)

Challenges in nuclear medicine: innovative theranostic tools for personalized medicine
by: Françoise eKraeber-Bodéré, et al.
Published: (2014-07-01)

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.
by: Appels, N, et al.
Published: (2008)

Phase I dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an inhaled recombinant human ACE2
by: Martin Bauer, et al.
Published: (2024-02-01)

Mek mulung
by: Malaysia. Kementerian Perpaduan, Kebudayaan, Kesenian dan Warisan. Jabatan Muzium dan Antikuiti, et al.
Published: ([dat)

Mek mulung
by: Malaysia. Kementerian Kebudayaan, Belia dan Sukan. Bahagian Kebudayaan
Published: (1981)

Vehicles on ro/ro ships
by: 8096 British Standards Institution, et al.

Ro-ro ships and shipping /
by: Grey, Michael
Published: (1985)

Safety, Pharmacokinetics/Pharmacodynamics, and Absolute Bioavailability of Dexmedetomidine Hydrochloride Nasal Spray in Healthy Subjects: A Randomized, Parallel, Escalating Dose Study
by: Yun Kuang, et al.
Published: (2022-05-01)

Real de-escalation or escalation in disguise?
by: Maggie Banys-Paluchowski, et al.
Published: (2023-06-01)

Ro/ro ships (1978-1978)
by: British Ship Research Association
Published: ([19-)

Consequences of escalation and de-escalation of double antiplatelet therapy in patients with acute coronary syndrome in real clinical practice
by: R. L. Shamraev, et al.
Published: (2019-04-01)

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
by: Marc A. Simon, et al.
Published: (2022-01-01)

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations
by: Xuan Wang, et al.
Published: (2023-01-01)

Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.
by: White, N, et al.
Published: (1999)

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
by: Pacey, S, et al.
Published: (2016)

Predicting Escalation
by: Jordan Arnold
Published: (2021-12-01)

On escalation and deterrence
by: Pool, Ithiel de Sola, 1917-1984
Published: (2014)

QUANTITATIVE EVALUATION OF THERAPEUTIC RESPONSE BY FDG PET-CT IN METASTATIC BREAST CANCER
by: Dorothée eGOULON, et al.
Published: (2016-05-01)

PHARMACOKINETICS AND PHARMACODYNAMICS OF DRUGS IN PATIENTS WITH RENAL DYSFUNCTION
by: K. Zakon, et al.
Published: (2017-12-01)

“Para ler ao som de Angela Ro Ro”
by: Carlos Alexandre da Silva Souza
Published: (2024-02-01)

Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial
by: Cai-De Jin, et al.
Published: (2021-06-01)

Improved survival with MEK inhibition in BRAF-mutated melanoma.
by: Flaherty, K, et al.
Published: (2012)

The Beginning and the Reasons of Escalation of the Civil War in Modern Russian Historiography
by: I. V. Mikhailov
Published: (2012-04-01)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
by: Elizabeth Turner, et al.
Published: (2022-11-01)

Immunological effects of BRAF+MEK inhibition
by: Paolo A. Ascierto, et al.
Published: (2018-09-01)

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
by: Boss, D, et al.
Published: (2010)

Editorial: The individualization of antiplatelet therapy in coronary artery disease: escalation or de-escalations
by: Sang Yeub Lee, et al.
Published: (2023-06-01)

The mechanisms of treatment resistance in psychiatry in the aspects of pharmacodynamics of psychotropic drugs
by: V. L. Kozlovskii
Published: (2018-07-01)

ADSORBABILITY OF “TALPUS-RO” AND “TALPUS-KK” MOULD
by: Larisa E. Pustovaya, et al.
Published: (2012-05-01)

Immuno-PET: Design options and clinical proof-of-concept
by: Alexandre Lugat, et al.
Published: (2022-10-01)

Pharmacokinetics and pharmacodynamics of curcumin.
by: Sharma, R, et al.
Published: (2007)

Assessment of Antifungal Pharmacodynamics
by: Alex Howard, et al.
Published: (2023-02-01)

Phase I dose escalation study of Linsitinib (OSI-906) and Erlotinib in patients with advanced solid tumors
by: Macaulay, V, et al.
Published: (2016)

DYSLIPIDEMIAS AND THEIR ASSOCIATION WITH CHRONIC NON-INFECTIOUS DISEASES (MERIDIAN-RO STUDY)
by: E. V. Filippov, et al.
Published: (2017-01-01)

EXPERT EVALUATION OF PRECLINICAL STUDIES OF PRIMARY AND SECONDARY PHARMACODYNAMICS OF MEDICINES
by: G. N. Engalycheva, et al.
Published: (2018-12-01)

Roles of Sulfites in Reverse Osmosis (RO) Plants and Adverse Effects in RO Operation
by: Yasushi Maeda
Published: (2022-01-01)

Yaw Motion Stability of an Indonesian Ro-Ro Ferry in Adverse Weather Conditions
by: Daeng Paroka
Published: (2020-10-01)